Moderna-Merck Cancer Vaccine Hits Milestone in Late-Stage Trial

A groundbreaking clinical trial has yielded positive results for an mRNA-based cancer vaccine. The vaccine, developed by Moderna and Merck, reduced the risk of melanoma recurrence when combined with Keytruda.

This breakthrough could pave the way for a new generation of cancer vaccines, but widespread misinformation about mRNA technology may undermine public confidence.

Misinformation surrounding mRNA vaccines has been spreading since the Covid-19 pandemic, with some people claiming that they cause unusually aggressive forms of cancer.